From: Clinical review: Anticoagulation for continuous renal replacement therapy - heparin or citrate?
 |  | Circuit life (hours)a | Bleeding | Transfusion (RBC/dayb) | Survival | ||||
---|---|---|---|---|---|---|---|---|---|
Reference | Design | Citrate | Heparin | Citrate | Heparin | Citrate | Heparin | Citrate | Heparin |
Monchi and colleagues [63] | RCOT, n = 20 | 70 (44 to 140), P < 0.001 | 40 (17 to 48) | n = 0 | n = 1 | 0.2 (0 to 0.4), P < 0.001 | 1.0 (0 to 2.0) | Â | Â |
Kutsogiannis and colleagues [64] | RCT, n = 30 | 125 (95 to 157), P < 0.001 | 38 (25 to 62) | RR 0.17 (0.03 to 1.04), P = 0.06 | Â | 0.53 (0.24 to 1.20), P = 0.13 | Â | Â | Â |
Betjes and colleagues [65] | RCT, n = 48 | Â | Â | 0%, P < 0.01 | 33% | 0.43, P = 0.01 | 0.88 | Â | Â |
Oudemans-Van Straaten and colleagues [35] | RCTc, n = 200 | 27 (13 to 47), NS | 26 (15 to 43) | 6%, P = 0.08 | 16% | 0.27 (0 to 0.63), P = 0.31 | 0.36 (0 to 0.83) | 52%d, P = 0.03 | 37%d |
Hetzel and colleagues [66] | RCT, n = 170 | 37.5 ± 23, P < 0.001 | 26.1 ± 19.2 | 14.5%, P = 0.06 | 5.7% |  |  | ± 30%e, NS | ± 43%e |